daré bioscience (nasdaq: dare) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. we are driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. we are initially focused on the areas of contraception, vaginal health and fertility. our lead product candidate, ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies.
Company profile
Ticker
DARE
Exchange
Website
CEO
Sabrina Martucci Johnson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cerulean Pharma Inc., Tempo Pharmaceuticals Inc
SEC CIK
Corporate docs
Subsidiaries
Daré Bioscience Operations, Inc. • Daré Bioscience Australia Pty Ltd • Pear Tree Pharmaceuticals, Inc. • Daré MBI Inc. ...
DARE stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
11 Sep 23
424B5
Prospectus supplement for primary offering
30 Aug 23
8-K
Daré Bioscience Announces $7.0 Million
30 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update
10 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
21 Jul 23
8-K
Daré to receive $1 million in July 2023 and $181.8 million in potential milestone payments from Organon under XACIATO global license agreement
5 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
22 Jun 23
8-K
Regulation FD Disclosure
5 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
Transcripts
DARE
Earnings call transcript
2023 Q2
10 Aug 23
DARE
Earnings call transcript
2023 Q1
11 May 23
DARE
Earnings call transcript
2022 Q4
30 Mar 23
DARE
Earnings call transcript
2022 Q3
11 Nov 22
DARE
Earnings call transcript
2022 Q2
10 Aug 22
DARE
Earnings call transcript
2022 Q1
13 May 22
DARE
Earnings call transcript
2021 Q4
1 Apr 22
DARE
Earnings call transcript
2021 Q3
11 Nov 21
DARE
Earnings call transcript
2021 Q2
13 Aug 21
DARE
Earnings call transcript
2021 Q1
14 May 21
Latest ownership filings
4
Cheryl R Blanchard
21 Jun 23
4
Jessica D. Grossman
21 Jun 23
4
Robin Joan Steele
21 Jun 23
4
Sophia Nnenna Ononye-Onyia
21 Jun 23
4
Susan L. Kelley
21 Jun 23
4
WILLIAM H RASTETTER
21 Jun 23
4
Gregory W Matz
21 Jun 23
4
SABRINA MARTUCCI JOHNSON
26 Jan 23
4
Lisa Walters-Hoffert
26 Jan 23
4
John A Fair
26 Jan 23
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 13.66 mm | 13.66 mm | 13.66 mm | 13.66 mm | 13.66 mm | 13.66 mm |
| Cash burn (monthly) | 2.06 mm | 1.53 mm | 3.00 mm | 3.40 mm | 2.20 mm | 1.67 mm |
| Cash used (since last report) | 6.04 mm | 4.51 mm | 8.80 mm | 9.97 mm | 6.45 mm | 4.90 mm |
| Cash remaining | 7.63 mm | 9.16 mm | 4.86 mm | 3.69 mm | 7.21 mm | 8.77 mm |
| Runway (months of cash) | 3.7 | 6.0 | 1.6 | 1.1 | 3.3 | 5.3 |
Institutional ownership, Q2 2023
10.5% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 31 |
| Opened positions | 4 |
| Closed positions | 5 |
| Increased positions | 3 |
| Reduced positions | 7 |
| 13F shares | Current |
|---|---|
| Total value | 5.11 bn |
| Total shares | 9.24 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 3.44 mm | $3.13 bn |
| Polaris Venture Partners Iii | 1.19 mm | $1.59 mm |
| Hawley Roger | 944.96 k | $869.00 k |
| Geode Capital Management | 817.34 k | $743.86 mm |
| Renaissance Technologies | 718.82 k | $654.00 k |
| CVI Investments | 599.90 k | $426.00 k |
| BLK Blackrock | 416.06 k | $378.66 mm |
| STT State Street | 247.71 k | $225.44 mm |
| Susquehanna International | 164.02 k | $149.28 mm |
| NTRS Northern Trust | 161.32 k | $146.81 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 21 Jun 23 | Matz Gregory W | Stock Option Common stock | Grant | Acquire A | No | No | 0.96 | 40,000 | 38.40 k | 40,000 |
| 21 Jun 23 | Rastetter William H | Stock Option Common stock | Grant | Acquire A | No | No | 0.96 | 40,000 | 38.40 k | 40,000 |
| 21 Jun 23 | Kelley Susan L. | Stock Option Common stock | Grant | Acquire A | No | No | 0.96 | 40,000 | 38.40 k | 40,000 |
| 21 Jun 23 | Sophia Nnenna Ononye-Onyia | Stock Option Common stock | Grant | Acquire A | No | No | 0.96 | 40,000 | 38.40 k | 40,000 |
| 21 Jun 23 | Steele Robin Joan | Stock Option Common stock | Grant | Acquire A | No | No | 0.96 | 40,000 | 38.40 k | 40,000 |
News
Daré Bioscience Announces Grant Funding Installment To Support Further Development Of Novel Contraceptive Technology DARE-LARC1; Daré May Receive A Total Of Up To Approximately $49 Million To Support Nonclinical Development Of DARE-LARC1
21 Sep 23
12 Health Care Stocks Moving In Wednesday's After-Market Session
20 Sep 23
Stocks That Hit 52-Week Lows On Monday
11 Sep 23
Stocks That Hit 52-Week Lows On Friday
8 Sep 23
Stocks That Hit 52-Week Lows On Wednesday
6 Sep 23
Press releases
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
21 Sep 23
Daré Bioscience to Present at The Menopause Society 2023 Annual Meeting
20 Sep 23
Daré Bioscience to Participate in Upcoming Investor Conferences
6 Sep 23
Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update
10 Aug 23
Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems
11 Jul 23